The landmark STEP 1 extension trial, published in Diabetes, Obesity and Metabolism (2022), followed participants after withdrawal of semaglutide 2.4 mg
As previously mentioned, the reaction of superoxide radicals with nitric oxide reduces NO bioavailability, leading to impaired endothelium-dependent vasodilation
10.1001/jamacardio.2020.4511 JAMA Cardiol
However, contact your doctor immediately or seek emergency help if your symptoms persist, worsen, or if you suspect an allergic reaction
Judith Baker NP Family Nurse Practitioner With over 15 years in healthcare, Judy is dedicated to caring for her community at every stage of life
(Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and other major diseases, announces that the first participant has been successfully dosed in a Phase 3 clinical trial (GLORY-2) of higher dose 9 mg mazdutide (Innovent R&D Code: IBI362) , a glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, in Chinese adults with obesity
